


1EW

Patent Application
Attorney Docket No. PC25541A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 29 day of July, 2004.

By


(Signature of person mailing)
Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Philip A. Carpino et al. :

APPLICATION NO.: 10/823,107 : Examiner: To be Advised

FILING DATE: 4/12/2004 : Group Art Unit: To be Advised

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


A first Office Action on the merits has not been received; therefore, no fee for this Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: July 27, 2004


Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25541A	SERIAL NO. 10/823,107
	APPLICANT Philip A. Carpino et al.	
	FILING DATE 4/12/2004	GROUP To be Advised

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 20010027193 A1	10/04/01	Achard, et al.			
	US 20010053788 A1	12/20/01	Lange, et al.			
	US 20020019383 A1	02/14/02	Achard, et al.			
	US 20020019421 A1	02/14/02	Biberman, et al.			
	US 20020035102 A1	03/21/02	Achard, et al.			
	US 20020091114 A1	07/11/02	Plot-Grosjean, et al.			
	US 20020119972 A1	08/29/02	Leftheris, et al.			
	US 20020128302 A1	09/12/02	Maruani, et al.			
	US 20020188007 A1	12/12/02	Barth, et al.			
	US 20030003145 A1	01/02/03	Abramovici, et al.			
	US 20030055033 A1	03/20/03	Achard, et al.			
	US 20030114495 A1	06/19/03	Finke, et al.			
	US 20030139386 A1	07/24/03	Cote, et al.			
	US 20030199536 A1	10/23/03	Thomas, et al.			
	US 20040077650 A1	4/22/04	Dow			
	US 20040092520 A1	5/12/04	Griffith			
	US 4,925,846	05/15/90	Deacon, et al.			
	US 4,944,790	07/31/90	Moser, et al.			
	US 5,134,142	07/28/92	Matsuo, et al.			
	US 5,462,960	10/31/95	Barth, et al.			
	US 5,596,106	01/21/97	Cullinan, et al.			
	US 5,624,941	04/29/97	Barth, et al.			
	US 5,744,491	04/28/98	Boigegrain, et al.			

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25541A		SERIAL NO. 10/823,107		
		APPLICANT Philip A. Carpino et al.				
		FILING DATE 4/12/2004		GROUP To be Advised		
	US 5,744,493	04/28/98	Boigegrain, et al.			
	US 5,747,524	05/05/98	Cullinan, et al.			
	US 5,925,768	07/20/99	Barth, et al.			
	US 6,028,084	02/22/00	Barth, et al.			
	US 6,100,259	08/08/00	Xiang, et al.			
	US 6,344,474 B1	02/05/02	Maruani, et al.			
	US 6,355,631 B1	03/12/02	Bouchard, et al.			
	US 6,432,984 B1	08/13/02	Barth, et al.			
	US 6,476,060 B2	11/05/02	Lange, et al.			
	US 6,479,479 B2	11/12/02	Achard, et al.			
	US 6,509,367 B1	01/21/03	Martin, et al.			
	US 6,518,264 B2	02/11/03	Achard, et al.			
	US 6,566,356 B2	05/20/03	Achard, et al.			
FOREIGN PATENT DOCUMENTS						
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
CA 2,387,138 equiv. to WO 01/028557 A1	04/26/01	CA				
US 2003087933 equiv. to WO 01/58450 A2	08/16/01	PCT				
US 5051518 equiv. to EP 293,220 B1	8/31/94	EP				
US 6642258 equiv. to WO 01/24798 A1	04/12/01	PCT				
WO 00/15609 A1	05/23/00	PCT				X
WO 01/029007 A1	04/26/01	PCT				
WO 01/032629 A1	05/10/01	PCT				X
WO 01/032663 A2	05/10/01	PCT				X
WO 01/85092 A2	11/15/01	PCT				X
WO 02/076949 A1	10/03/02	PCT				

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25541A		SERIAL NO. 10/823,107			
		APPLICANT Philip A. Carpino et al.					
		FILING DATE 4/12/2004		GROUP To be Advised			
	WO 03/006007 A1	01/23/03	PCT				
	WO 03/007887 A2	01/30/03	PCT				
	WO 03/018060 A1	03/06/03	PCT				X
	WO 03/020217 A2	03/13/03	PCT				
	WO 03/020314 A1	03/13/03	PCT				X
	WO 03/026647 A1	04/03/03	PCT				
	WO 03/026648 A1	04/03/03	PCT				
	WO 03/027069 A1	04/03/03	PCT				
	WO 03/027076 A2	04/03/03	PCT				
	WO 03/027114 A1	04/03/03	PCT				
	WO 03/040107 A1	05/15/03	PCT				
	WO 03/051850 A1	06/26/03	PCT				
	WO 03/051851 A1	06/26/03	PCT				
	WO 03/075660 A1	09/18/03	PCT				
	WO 03/077847 A2	09/25/03	PCT				
	WO 03/078413 A1	09/25/03	PCT				
	WO 03/082190 A2	10/09/03	PCT				
	WO 03/082191 A2	10/09/03	PCT				
	WO 03/082256 A2	10/09/03	PCT				X
	WO 03/082833 A1	10/09/03	PCT				X
	WO 03/084943 A2	10/16/03	PCT				X
	WO 03/086288 A2	10/23/03	PCT				
	WO 03/087037 A1	10/23/03	PCT				
	WO 04/012617 A2	02/12/04	PCT				
	WO 96/02248 A1	02/01/96	PCT				

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25541A	SERIAL NO. 10/823,107
		APPLICANT Philip A. Carpino et al.	
		FILING DATE 4/12/2004	GROUP To be Advised
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Tzavara, E.T., et al., "The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions," <u>J Pharmacol</u> , 138 , 544-553 (2003).	
		Racz, I., et al., "A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking," <u>J Neurosci</u> , 23 (6), 2453-2458 (2003).	
		Crocì, T., et al., "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor- α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents," <u>Brit J Pharmacol</u> , 140 , 115-122 (2003).	
		DaSilva, G.E., et al., "Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats," <u>Neurosci Lett</u> , 349 , 49-52 (2003).	
		Wang, L., et al., "Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice," <u>PNAS</u> , 100 (3), 1393-1398 (2003).	
		Ruii, S., et al., "Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor," <u>J Pharmacol Exp Therap</u> , 306 , 363-370 (2003).	
		Howlett, A.C., et al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors," <u>Pharmacol Rev</u> , 54 , 161-202 (2002).	
		Gomez, R., et al., "A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding," <u>J. Neurosci</u> , 22 (21), 9612-9617 (2002).	
		Wiley, J.L., et al., "Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation," <u>J Pharmacol Exp Therap</u> , 296 (3), 1013-1022 (2001).	
		Lellemand, F., et al., "Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration," <u>Alcohol Clin Exp Res</u> , 25 (9), 1317-1323 (2001).	
		Pertwee, R.G., "Cannabinoids and the Gastrointestinal Tract," <u>Gut</u> , 48 , 859-867 (2001).	
		Pertwee, R.G., "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," <u>Exp. Opin. Invest. Drugs</u> , 9 (7), 1573-1571 (2000).	
		Hungund, B.L and B.S. Basavarajappa, "Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence," <u>Alcohol & Alcoholism</u> , 35 (2) 126-133, (2000).	
		Freedland, C.S., et al., "Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding," <u>Pharmacol Biochem Behav</u> , 67 , 265-270 (2000).	
		Lan, R., et al., "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists" <u>J. Med. Chem</u> , 42 , 769-776 (1999).	
		Pertwee, R.G., "Pharmacology of Cannabinoid Receptor Ligands" <u>Curr Med Chem</u> , 6 , 635-664 (1999).	
		Basavarajappa, B.S., et al., "Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane," <u>Brain Res</u> , 793 , 212-218 (1998).	
		Thomas, B.F., et al., "Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists," <u>J Pharmacol Exp Therap</u> , 285 , 285-292 (1998).	
		Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," <u>Life Sci.</u> , 63 , PL113-PL117 (1998);	
		Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmoset," <u>Behav. Pharmacol.</u> , 9 , 179-181 (1998).	
		Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," <u>Psychopharmacology</u> , 135 , 324-332 (1998).	
		Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," <u>Psychopharmacol</u> , 132 , 104-106 (1997).	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25541A	SERIAL NO. 10/823,107
		APPLICANT Philip A. Carpino et al.	
		FILING DATE 4/12/2004	GROUP To be Advised
		Savontaus, E., et al., "Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Genetic Obesity," <u>Eur J Pharmacol</u> , 328 , 207-215 (1997).	
		Sanudo-Pena, M.C., et al., "Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat," <u>Neurosci Lett</u> , 223 , 125-128 (1997).	
		Gifford, A.N., et al., "Electrically Evoked Acetylcholine Release from Hippocampal Silices is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A," <u>J Pharmacol Exp Ther</u> , 277 , 1431-1436 (1996).	
		Compton, D.R., et al., "In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity," <u>J Pharmacol Exp Ther</u> , 277 , 586-594 (1996).	
		Mansbach, R.S., et al., "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats," <u>Psychopharmacology</u> , 124 , 315-322 (1996).	
		Lichtman, A.H., et al., "Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism," <u>Psychopharmacology</u> , 126 , 125-131 (1996).	
		Perio, A., et al., "Central Mediation of the Cannabinoid Cue: Activity of a Selective CB1 Antagonist, SR141716A," <u>Behavioral Pharmacology</u> , 7 , 65-71 (1996).	
		Rinaldi-Carmona, M., et al., "Biochemical and Pharmacological Characterization of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist," <u>Life Sci</u> , 56 , 1941-1947 (1995).	
		Pertwee, R., et al., "AM630, A Competitive Cannabinoid Receptor Antagonist," <u>Life Sci</u> , 56 , 1949-1955 (1995).	
		Rinaldi-Carmona, M., et al., "SR141716A, a Potent and Selective Antagonist of the Brain Cannabinoid Receptor," <u>FEBS Letters</u> , 350 , 240-244 (1994).	
		Dutta, A., et al., "The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A," <u>Med. Chem. Rev.</u> 5 , 54-62 (1994).	
		Drummond, J., et al., "Evaluation and Synthesis of Aminohydroxyisoxazoles and Pyrazoles as Potential Glycine Agonists," <u>J. Med. Chem.</u> , 32 , 2116-2128 (1989).	
		Murray, W., et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-carboxylates" <u>J. Heterocyclic Chem.</u> , 26 , 1389 (1989).	
		Dewey, W.L. "Cannabinoid Pharmacology," <u>Pharmacological Reviews</u> , 38 (2)m 151-178 (1986).	
		Tewari, R.S., et al., "1,3-Dipolar Cycloaddition and Nucleophilic Substitution Reactions of C-Acetyl and C-Ethoxycarbonyl Derivative of Hydrazidoyl Bromides" <u>Tetrahedron</u> , 39 (1) 129-136 (1983).	
		Birkofer, L. and K. Richtzenhain, "Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol" <u>Chem. Ber.</u> 112 , 2829-2836 (1979).	
		Franke, H. et al., "Polare Cycloadditionen von elektronenreichen Mehrfach-bindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadiazolo[3,2-a]chinolinen" <u>Chem. Ber.</u> 112 , 3623-3636 (1979).	
		Sucrow, W., et al., "Bimolekulare Cyclisierung von 2-(1-Methylhydrazino)maleinsäure-dimethylester" <u>Chem. Ber.</u> 112 , 1712-1718 (1979).	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			